Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSI June 2026 Index Rebalance: Pre-Implementation Update

HSI Index Rebalance: March 2026 Post-Event Review

HSI Index Rebalance: Historical Patterns & March '25 Analysis

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>Hang Seng Indexes announced three HSI ADDs and no DELETE for the May 2026 review after market close.</li>
<li>We reviewed three ADDs against 13 prior HSI rebalance cycles and the completed post announcement setup.</li>
<li>The prior forecast identified BeOne and no DELETE, while J&amp;T Express and Chalco were outside the forecast slate.</li>
</ul>


Hang Seng Indexes announced three HSI ADDs and no DELETE for the May 2026 review after market close.
We reviewed three ADDs against 13 prior HSI rebalance cycles and the completed post announcement setup.
The prior forecast identified BeOne and no DELETE, while J&amp;T Express and Chalco were outside the forecast slate.


HSI June 2026 Index Rebalance: Post-Announcement Positioning

BeOne Medicines

HSI June 2026 Index Rebalance: Post-Announcement Positioning